Biotech · Private company
ApoPharma
Track this companyFree. Adds ApoPharma to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- Deferiprone oral solutionPhase 3 · Pantothenate Kinase-Associated NeurodegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Deferiprone DR tablets 1000 mg (High dosage)Phase 2 · Iron Overload Due to Repeated Red Blood Cell TransfusionsClinicalTrials.gov · fetched Nov 12, 2026
- Deferiprone DR tablets 1000 mg (Low dosage)Phase 2 · Iron Overload Due to Repeated Red Blood Cell TransfusionsClinicalTrials.gov · fetched Nov 12, 2026
- DeferiproneIron OverloadClinicalTrials.gov · fetched Nov 12, 2026
- DeferoxamineIron OverloadClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron OverloadPHASE2 · COMPLETED · started Mar 6, 2019ClinicalTrials.gov NCT03802916 · fetched Nov 12, 2026
- Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasPHASE4 · TERMINATED · started May 21, 2015ClinicalTrials.gov NCT02443545 · fetched Nov 12, 2026
- Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated NeurodegenerationPHASE3 · COMPLETED · started Jun 1, 2014ClinicalTrials.gov NCT02174848 · fetched Nov 12, 2026
- Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasPHASE4 · TERMINATED · started Apr 17, 2014ClinicalTrials.gov NCT02041299 · fetched Nov 12, 2026
- Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)PHASE3 · COMPLETED · started Dec 13, 2012ClinicalTrials.gov NCT01741532 · fetched Nov 12, 2026